Yahoo Finance Did You Miss BARD1 Life Sciences's (ASX:BD1) 38% Share Price Gain?
The last three months have been tough on BARD1 Life Sciences Limited (ASX:BD1) shareholders, who have seen the share price decline a rather worrying 39%. But that doesn't change the reality that over twelve months the stock has done really well. In that time we've seen the stock easily surpass the market return, with a gain of 38%.
Check out our latest analysis for BARD1 Life Sciences
We don't think BARD1 Life Sciences's revenue of AU$598,096 is enough to establish significant demand. As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. It seems likely some shareholders believe that BARD1 Life Sciences will significantly advance the business plan before too long.
We think companies that have neither significant revenues nor profits are pretty high risk. There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. While some companies like this go on to deliver on their plan, making good money for shareholders, many end in painful losses and eventual de-listing.
When it last reported its balance sheet in December 2019, BARD1 Life Sciences could boast a strong position, with cash in excess of all liabilities of AU$8.1m. This gives management the flexibility to drive business growth, without worrying too much about cash reserves. And with the share price up 134% in the last year , the market is focussed on that blue sky potential. You can see in the image below, how BARD1 Life Sciences's cash levels have changed over time (click to see the values).
In reality it's hard to have much certainty when valuing a business that has neither revenue or profit. One thing you can do is check if company insiders are buying shares. If they are buying a significant amount of shares, that's certainly a good thing. Luckily we are in a position to provide you with this free chart of insider buying (and selling).
What about the Total Shareholder Return (TSR)?
We've already covered BARD1 Life Sciences's share price action, but we should also mention its total shareholder return (TSR). Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. We note that BARD1 Life Sciences's TSR, at 39% is higher than its share price return of 38%. When you consider it hasn't been paying a dividend, this data suggests shareholders have benefitted from a spin-off, or had the opportunity to acquire attractively priced shares in a discounted capital raising.
A Different Perspective
It's nice to see that BARD1 Life Sciences shareholders have gained 39% (in total) over the last year. What is absolutely clear is that is far preferable to the dismal 8.9% average annual loss suffered over the last three years. We're generally cautious about putting too much weigh on shorter term data, but the recent improvement is definitely a positive. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 6 warning signs for BARD1 Life Sciences (3 don't sit too well with us) that you should be aware of.
BARD1 Life Sciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
